undamentalytics Newsletter
Sign in

Cogent Biosciences, Inc. (COGT) stock

Add to watchlist

Add holding +

NASDAQ: COGT Nasdaq Biotechnology Next results ~November 3, 2026

Cogent Biosciences, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: data-quality checks not passed.

Price vs value

Under review: data-quality checks not passed. We'll show the comparison once resolved.

Cogent Biosciences, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 6 selling0 purchases and 8 sales by directors and officers, last 12 monthsInsider trades
  • Funds196 adding, 126 cuttingOf 69 active managers that changed their stake, 37 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~November 3, 2026 (estimated)

Current signal Revenue growth decelerating: TTM revenue growth slowed to -65.0% (-175.2pp vs the prior quarter).

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Cogent Biosciences, Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Revenue shrinking. Revenue fell 65.0% over the last 12 months.
  • Growth slowing. The growth rate is 175.2 points lower than a quarter earlier.
  • Loss-making. Operating margin is -1044.3%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 901.3 points on a year ago.
  • Burning cash. Free cash flow was -184.7% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 76.4% of revenue: a real cost that cash-flow figures leave out.

Latest results: FY2020 Q4

Filed March 15, 2022
Earnings per share
-$0.52 against an average estimate of -$0.56: beat by 8.0%
Share reaction
-8.7% in the first session after the results on August 10, 2026, against -0.3% for the S&P 500
Next report
November 3, 2026; average EPS estimate -$0.55

Cogent Biosciences' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-4.2%
  • 1 week-3.8%
  • 1 month-4.2%
  • This year-16.3%
  • 1 year+82.4%
  • 5 years+234.4%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

EPS (TTM, diluted)
$-2.43

Growth

Share count change
+38.3%

Earnings

Last results
August 10, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Agreement
  2. Insider trade
  3. Announcement
  4. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Cogent Biosciences, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: data-quality checks not passed.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 3, 2026, before the open. Analysts expect revenue of $0 and EPS of −$0.55 (range −$0.64 to −$0.45) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$2.22 −5% $6m 0%
Next −$1.20 +46% $284m +4637%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −1.8% on 90 days ago. In the last 30 days, 4 analysts raised Cogent Biosciences, Inc.'s forecast and 4 cut it.

Consensus EPS forecast Cogent Biosciences, Inc., last 90 days
−$3.00 −$2.00 −$1.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$2.26 Current fiscal year, 60 days ago: −$2.21 Current fiscal year, 30 days ago: −$2.21 Current fiscal year, 7 days ago: −$2.21 Current fiscal year, Now: −$2.22 −$2.22 Next fiscal year, 90 days ago: −$0.94 Next fiscal year, 60 days ago: −$1.11 Next fiscal year, 30 days ago: −$1.11 Next fiscal year, 7 days ago: −$1.18 Next fiscal year, Now: −$1.20 −$1.20

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$2.26−$0.94
60 days ago −$2.21−$1.11
30 days ago −$2.21−$1.11
7 days ago −$2.21−$1.18
Now −$2.22−$1.20

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.56 −$0.52 +8.0%
Mar 2026 −$0.54 −$0.53 +1.9%
Dec 2025 −$0.51 −$0.56 −10.5%
Sept 2025 −$0.52 −$0.50 +3.2%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

12 analysts, Oct 2026
Buy1192%
Hold18%
Sell00%

Monthly trend

  1. Oct 202629112
  2. Sep 202629112
  3. Aug 202629112
  4. Jul 202629213

Counts of recommendations published by analysts covering Cogent Biosciences, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
11.4%
of tradable shares
Days to cover
8.48
at average volume
Short interest, 1 month
+8%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
0.4%
of shares
Employees
258
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
COGT−24%+35%−49%+33%+355%−16%
Industry peers (median)−36%−57%−17%−29%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
COGT42%33%33%58%67%36%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
COGT−52%−56%−74%−38%−58%−34%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since March 29, 2018: 98% from July 31, 2018 to March 16, 2020. Getting back needed a 5141% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$14.13 – $42.84
From 52-week high
−30.6%
vs 50-day average
−7.9%
vs 200-day average
−16.6%
Volatility (1 year)
127%
Beta vs S&P 500
2.52

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
4 up, 8 down
typical move ±6.3%
After a week
3 up, 9 down
typical move ±15.3%
After a month
6 up, 6 down
typical move ±23.8%
Results releasedNext dayS&P 500 next day5 days21 days
August 10, 2026 −8.7% −0.3% −10.7% −19.4%
May 5, 2026 −2.3% +2.2% −6.0% −10.7%
February 17, 2026 +5.0% +0.7% +7.3% −5.9%
November 3, 2025 −13.3% −1.0% +99.1% +140.2%
August 5, 2025 −9.0% +0.3% −4.1% +7.4%
July 10, 2025 +5.6% −0.1% +17.3% +5.4%
May 6, 2025 −15.3% −0.4% −10.4% +7.5%
February 25, 2025 −10.1% −0.4% −3.9% −13.3%
November 12, 2024 0.0% −0.3% −12.9% −19.8%
August 6, 2024 −5.6% +0.2% −4.0% +23.0%
May 7, 2024 +0.4% +0.1% −2.9% +11.1%
February 26, 2024 +0.7% −0.2% −5.2% −21.6%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Revenue (TTM) Cogent Biosciences, Inc.
$0 $10M $20M $30M FY18 Q1 FY18 Q4 FY19 Q3 FY20 Q4 Revenue (TTM), FY18 Q1: $8.8M Revenue (TTM), FY18 Q2: $8.3M Revenue (TTM), FY18 Q3: $8.1M Revenue (TTM), FY18 Q4: $9.7M Revenue (TTM), FY19 Q1: $10.6M Revenue (TTM), FY19 Q2: $12M Revenue (TTM), FY19 Q3: $11M Revenue (TTM), FY19 Q4: $22.5M Revenue (TTM), FY20 Q1: $26.5M Revenue (TTM), FY20 Q2: $23.9M Revenue (TTM), FY20 Q3: $23.2M Revenue (TTM), FY20 Q4: $7.9M $7.9M

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue (TTM)
FY18 Q1 $8.8M
FY18 Q2 $8.3M
FY18 Q3 $8.1M
FY18 Q4 $9.7M
FY19 Q1 $10.6M
FY19 Q2 $12M
FY19 Q3 $11M
FY19 Q4 $22.5M
FY20 Q1 $26.5M
FY20 Q2 $23.9M
FY20 Q3 $23.2M
FY20 Q4 $7.9M
Revenue growth, TTM YoY Cogent Biosciences, Inc.
-100% 0% 100% 200% FY18 Q4 FY19 Q2 FY19 Q4 FY20 Q2 FY20 Q4 Revenue growth, TTM YoY, FY18 Q4: 16.4% Revenue growth, TTM YoY, FY19 Q1: 20.7% Revenue growth, TTM YoY, FY19 Q2: 44.4% Revenue growth, TTM YoY, FY19 Q3: 36.8% Revenue growth, TTM YoY, FY19 Q4: 131.1% Revenue growth, TTM YoY, FY20 Q1: 150.6% Revenue growth, TTM YoY, FY20 Q2: 98.2% Revenue growth, TTM YoY, FY20 Q3: 110.2% Revenue growth, TTM YoY, FY20 Q4: -65.0% -65.0%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue growth, TTM YoY
FY18 Q4 16.4%
FY19 Q1 20.7%
FY19 Q2 44.4%
FY19 Q3 36.8%
FY19 Q4 131.1%
FY20 Q1 150.6%
FY20 Q2 98.2%
FY20 Q3 110.2%
FY20 Q4 -65.0%
Operating margin (TTM) Cogent Biosciences, Inc.
-1500% -1000% -500% 0% FY18 Q1 FY18 Q4 FY19 Q3 FY20 Q4 Operating margin (TTM), FY18 Q1: -309.3% Operating margin (TTM), FY18 Q2: -365.4% Operating margin (TTM), FY18 Q3: -420.8% Operating margin (TTM), FY18 Q4: -369.9% Operating margin (TTM), FY19 Q1: -386.7% Operating margin (TTM), FY19 Q2: -348.6% Operating margin (TTM), FY19 Q3: -394.2% Operating margin (TTM), FY19 Q4: -143.0% Operating margin (TTM), FY20 Q1: -100.0% Operating margin (TTM), FY20 Q2: -97.8% Operating margin (TTM), FY20 Q3: -295.8% Operating margin (TTM), FY20 Q4: -1044.3% -1044.3%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Operating margin (TTM)
FY18 Q1 -309.3%
FY18 Q2 -365.4%
FY18 Q3 -420.8%
FY18 Q4 -369.9%
FY19 Q1 -386.7%
FY19 Q2 -348.6%
FY19 Q3 -394.2%
FY19 Q4 -143.0%
FY20 Q1 -100.0%
FY20 Q2 -97.8%
FY20 Q3 -295.8%
FY20 Q4 -1044.3%
FCF margin (TTM) Cogent Biosciences, Inc.
-400% -300% -200% -100% 0% FY17 Q4 FY18 Q2 FY18 Q4 FY19 Q2 FY19 Q4 FCF margin (TTM), FY17 Q4: -319.9% FCF margin (TTM), FY18 Q1: -310.9% FCF margin (TTM), FY18 Q2: -354.2% FCF margin (TTM), FY18 Q3: -380.5% FCF margin (TTM), FY18 Q4: -339.4% FCF margin (TTM), FY19 Q1: -345.8% FCF margin (TTM), FY19 Q2: -328.8% FCF margin (TTM), FY19 Q3: -382.3% FCF margin (TTM), FY19 Q4: -184.7% -184.7%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period FCF margin (TTM)
FY17 Q4 -319.9%
FY18 Q1 -310.9%
FY18 Q2 -354.2%
FY18 Q3 -380.5%
FY18 Q4 -339.4%
FY19 Q1 -345.8%
FY19 Q2 -328.8%
FY19 Q3 -382.3%
FY19 Q4 -184.7%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020
Income
Revenue 8 10 22 8
EBITDA −25 −35 −31 −81
Operating income −26 −36 −32 −82
Net income −25 −35 −32 −75
Diluted EPS −$2.51 −$1.39 −$4.18 −$16.17
Growth (year on year)
Revenue — +16.4% +131.1% −65.0%
Margins
EBITDA margin −298.8% −356.3% −137.3% <−999%
Operating margin −312.8% −369.9% −143.0% <−999%
Net margin −304.9% −354.8% −141.5% −950.4%
Free-cash-flow margin −319.9% −339.4% −184.7% —
Cash flow
Cash from operations −26 −32 −42 −36
Capital spending 1 1 0 —
Free cash flow −27 −33 −42 —
Stock-based pay 1 3 3 6
Free cash flow after stock pay −28 −36 −45 —
Balance sheet
Cash 28 56 37 242
Total debt 0 0 0 0
Net debt (negative = net cash) −28 −56 −37 −242
Diluted shares 3m 6m 8m 11m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Dividends, buybacks and capital spending

Diluted share count
+38.3%
year over year

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated COGT COYA ADAG ACRS ROIV EVAX Median
Revenue, last 12 months $8m $8m $8m $8m $8m $8m $55m
Revenue growth, last 12 months −65.0% >999% >999% −51.0% −67.6% 125.1% 12.2%
Revenue growth, 3-year average −2.0% — — −35.9% −46.4% — 13.1%
Revenue growth, latest quarter −100.0% 49.0% — −8.3% −33.5% — 10.2%
Operating margin <−999% −288.7% −279.5% <−999% <−999% −122.7% −191.1%
Operating margin, 3-year average −519.1% <−999% — −711.4% −102.3% — −365.3%
Net margin −950.4% −270.2% −229.6% −921.5% <−999% −102.4% −172.8%
Cash from operations / revenue −455.5% −196.1% −204.1% −755.1% <−999% −88.0% −168.8%
Free-cash-flow margin −184.7% −196.3% −204.3% −756.5% <−999% −88.2% −168.1%
Free-cash-flow margin, 3-year average −281.3% <−999% — −339.9% <−999% — −306.5%
Stock pay / revenue 76.4% 66.3% 48.8% 141.8% >999% 4.1% 20.7%
Change in share count 38.3% 22.4% 4.8% 25.5% 0.6% 497.3% 8.3%

Median of all 185 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Who owns it

Funds buying and selling
Reported value
$7.6B
Institutions reporting
320
Shares held vs prior quarter
▲ 4.6%
Positions opened / closed
60 / 41

Top buyers and sellers, Q2 2026: 196 institutions bought and 126 sold ; the biggest buyer was Polar Capital Holdings PLC (+3.2M shares) and the biggest seller Deerfield Management Company, L.P (−4.0M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
FMR LLC $994M 25.7M 13.2% ▲ 11.1%
Blackrock, Inc. $672M 17.4M 8.9% ▲ 8.1%
Vanguard Portfolio Management LLC $312M 8.1M 4.1% ▲ 10.1%
Vanguard Capital Management LLC $287M 7.4M 3.8% ▲ 7.5%
State Street Corp $270M 7.0M 3.6% ▲ 23.0%
Jupiter Topco LLC $256M 6.6M 3.4% —
Fairmount Funds Management LLC $213M 5.5M 2.8% 0.0%
Deerfield Management Company, L.P. $194M 5.0M 2.6% ▼ 44.6%
Tcg Crossover Management, LLC $188M 4.9M 2.5% ▼ 1.9%
Price T Rowe Associates Inc $180M 4.7M 2.4% ▲ 44.8%
Geode Capital Management, LLC $175M 4.5M 2.3% ▲ 21.9%
Wellington Management Group LLP $168M 4.3M 2.2% ▲ 21.4%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Cogent Biosciences, Inc.'s complete shareholder register. Values are as reported by the filers ; 4 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $384M 8 trades by 6 insiders · 0% under pre-set plans
Net ▼ $384M net selling
Insider Date Trade Shares Price Value
Morris Arlene Director August 27, 2026 Sell pre-set plan 42,349 $37.09 $1.6M
Morris Arlene Director August 27, 2026 Sell pre-set plan 3,161 $37.54 $118,664
Fairmount Funds Management Llc Director March 31, 2026 Sell 7,000,000 $34.66 $243M
Fairmount Funds Management Llc Director January 22, 2026 Sell 3,500,000 $36.40 $127M
Robinson John Edward Chief Scientific Officer December 26, 2025 Sell 90,000 $38.74 $3.5M
Sachs Jessica Chief Medical Officer December 26, 2025 Sell 82,642 $38.70 $3.2M
Green John L. Chief Financial Officer December 26, 2025 Sell 77,000 $38.68 $3M
Kearns Evan Chief Legal Officer December 26, 2025 Sell 65,000 $38.70 $2.5M

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 1 trade and filings

No trades in Cogent Biosciences, Inc. disclosed in the last 12 months; 1 earlier trade on record.

  • Chris Jacobs(R-NY 27):Purchase, $1,001 - $15,000, traded December 12, 2022, filed January 20, 2023

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around November 2, 2026 estimated from the company's past filing pattern, not announced

  • August 10, 2026
  • May 5, 2026
  • February 17, 2026
  • November 3, 2025
  • August 5, 2025
  • July 10, 2025

Recent SEC filings

Data status

When each part of this page on Cogent Biosciences, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Cogent Biosciences, Inc. in brief

What does Cogent Biosciences, Inc. do?
Cogent Biosciences, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Cogent Biosciences, Inc.'s stock ticker?
Cogent Biosciences, Inc. trades under the ticker COGT on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Cogent Biosciences, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are FMR LLC, Blackrock, Inc. and Vanguard Portfolio Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Cogent Biosciences, Inc.'s market cap?
On December 31, 2020, Cogent Biosciences, Inc.'s market capitalisation was about $124M and net debt of -$242M. Market figures come from third-party market data and may be delayed.
Who are Cogent Biosciences, Inc.'s competitors?
In our Biotechnology peer group, the companies closest to Cogent Biosciences, Inc. are Coya Therapeutics, Inc., Adagene Inc., Aclaris Therapeutics, Inc., Roivant Sciences Ltd. and Evaxion A/s. The side-by-side comparison below sets their revenue, margins and growth against Cogent Biosciences, Inc.'s.
Are insiders buying or selling Cogent Biosciences, Inc. stock?
Over the last 12 months, Cogent Biosciences, Inc.'s directors and officers reported 0 open-market purchases and 8 sales on Form 4. The insider trading page charts every trade.
When is Cogent Biosciences, Inc.'s next earnings date?
Around November 3, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Cogent Biosciences, Inc. announces its own schedule.